Bioanalytical and biomarker assay development for COVID-19 Therapeutics and Vaccines

Bioanalytical and biomarker assay development for COVID-19 Therapeutics and Vaccines

Contract Research

Information

All clinical trials for COVID-19 need PCR assays that detect the virus and determine an active infection. Antibody and neutralizing assays are necessary to identify if a therapy or vaccine produces antibodies against the virus. There are also essential biomarkers to measure in COVID-19 trials. Cytokines can be measured in the blood to characterize the cytokine storm that SARS-CoV-2 creates in the lungs. Other functional biomarker assays such as the ELISPOT determine if T cells are helping produce antibodies after vaccination.
CelerionTranslating science into medicine, Celerion is a premier, global provider of early clinical research. We recognize that access to experts and regulatory guidance at the appropriate times of your vaccine development plan are critical for your success. We have the experience and expertise to assist with these discussions and provide guidance into crucial early clinical development as well as pivotal efficacy and safety studies. Celerion’s expertise spans a large variety of vaccines within Infectious Diseases, Oncology, and Autoimmune Diseases. Our experience includes both preventive and therapeutic vaccines across all phases and many different routes of administration, and patient populations.

Log in